Glucose metabolism disorders and changes in cardiovascular risk among adult Peruvian population
Jhohann Sedano-Espinoza, Kevin Perez-Ochoa, Erick Yalico-Quispe, Antonio Bernabe-Ortiz, Paul Anthony Camacho Lopez, Antonio Bernabe-Ortiz
TL;DR
This study shows that people with prediabetes and type 2 diabetes in Peru have higher cardiovascular risk and blood pressure compared to those with normal glucose levels.
Contribution
The study provides new evidence on the long-term cardiovascular risk associated with glucose metabolism disorders in a Peruvian population.
Findings
At baseline, individuals with prediabetes and diabetes had higher cardiovascular risk and mean arterial pressure.
After six years, mean arterial pressure decreased more in people with normal glucose levels than in those with prediabetes or diabetes.
Cardiovascular risk remained unchanged over time, but mean arterial pressure was still higher in those with glucose metabolism disorders.
Abstract
Rates of cardiovascular diseases are increasing annually, and glucose metabolism disorders play an important role in cardiovascular risk. This study aimed to assess changes in cardiovascular risk over time according to the levels of blood glucose, especially prediabetes and type 2 diabetes. Prospective cohort study conducted in the northern Peru. Two were the outcomes of interest, evaluated at the cohort’s baseline and six years after: cardiovascular risk (in percentage), defined using the laboratory-free risk score (HEARTS from the World Health Organization), and the mean arterial pressure (in mmHg); whereas the exposure was glucose metabolism disorder, especially prediabetes and type 2 diabetes, compared to normoglycaemia. Associations were evaluated using mixed linear regression models, and coefficients (β) and 95% confidence intervals (95% CI) were reported. A total of 1607…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Normal | Prediabetes | Type 2 diabetes | p-valor | |
|---|---|---|---|---|
| (n = 1159) | (n = 272) | (n = 176) | ||
|
| <0,001 | |||
| Men | 612 (52.8%) | 112 (41.2%) | 74 (42.0%) | |
| Women | 547 (47.2%) | 160 (58.8%) | 102 (58.0%) | |
|
| <0.001 | |||
| <40 years | 372 (32.1%) | 54 (19.9%) | 14 (7.9%) | |
| 40-49 years | 354 (30.5%) | 81 (29.8%) | 45 (25.6%) | |
| 50-59 years | 264 (22.8%) | 76 (27.9%) | 69 (39.2%) | |
| 60+ years | 169 (14.6%) | 61 (22.4%) | 48 (27.3%) | |
|
| <0.001 | |||
| Primary | 336 (29.0%) | 102 (37.5%) | 80 (45.5%) | |
| Secondary | 559 (48.2%) | 116 (42.7%) | 73 (41.5%) | |
| Superior | 264 (22.8%) | 54 (19.8%) | 23 (13.0%) | |
|
| 0.29 | |||
| Low | 370 (31.9%) | 100 (36.8%) | 68 (38.6%) | |
| Middle | 408 (35.2%) | 89 (32.7%) | 53 (30.1%) | |
| High | 381 (32.9%) | 83 (30.5%) | 55 (31.3%) | |
|
| 0.26 | |||
| No | 100 (9.4%) | 20 (7.3%) | 11 (6.2%) | |
| Yes | 1050 (90.6%) | 252 (92.7%) | 165 (93.8%) | |
|
| 0.40 | |||
| No | 1087 (93.8%) | 260 (95.6%) | 168 (95.5%) | |
| Yes | 72 (6.2%) | 12 (4.4%) | 8 (4.5%) | |
|
| 0.002 | |||
| ≤1 per month | 1030 (88.9%) | 259 (95.2%) | 165 (93.8%) | |
| >1 per month | 129 (11.1%) | 13 (4.8%) | 11 (6.2%) | |
|
| 0.02 | |||
| Moderate/high | 744 (64.2%) | 165 (60.7%) | 94 (53.4%) | |
| Low | 415 (35.8%) | 107 (39.3%) | 82 (46.6%) | |
|
| 0.85 | |||
| <1 per day | 548 (47.3%) | 133 (48.9%) | 86 (48.9%) | |
| ≥=1 per day | 611 (52.7%) | 139 (51.1%) | 90 (51.1%) | |
|
| <0.001 | |||
| No | 855 (73.8%) | 158 (58.1%) | 118 (67.1%) | |
| Yes | 304 (26.2%) | 114 (41.9%) | 58 (32.9%) | |
|
| <0.001 | |||
| No | 907 (78.3%) | 179 (65.8%) | 104 (59.1%) | |
| Yes | 252 (21.7%) | 93 (34.2%) | 72 (40.9%) | |
| N | Cardiovascular risk
| Mean blood pressure
| |||
|---|---|---|---|---|---|
| Mean (SD) | p-value | Mean (SD) | p-value | ||
|
| <0.001 | <0.001 | |||
| Men | 798 | 3.8 (2.8) | 95.7 (11.2) | ||
| Women | 809 | 2.3 (2.0) | 90.5 (12.0) | ||
|
| <0.001 | <0.001 | |||
| <40 years | 440 | 1.1 (0.8) | 88.5 (9.3) | ||
| 40-49 years | 480 | 1.9 (1.2) | 92.4 (11.2) | ||
| 50-59 years | 409 | 3.7 (1.7) | 95.6 (12.0) | ||
| 60+ years | 278 | 6.8 (2.5) | 97.8 (13.5) | ||
|
| <0.001 | <0.001 | |||
| Primary | 518 | 4.3 (2.8) | 95.1 (12.5) | ||
| Secondary | 748 | 2.6 (2.3) | 92.8 (11.5) | ||
| Superior | 341 | 1.9 (1.6) | 90.6 (11.1) | ||
|
| 0.01 | 0.41 | |||
| Low | 538 | 3.3 (2.6) | 93.3 (11.7) | ||
| Middle | 550 | 2.9 (2.5) | 92.5 (11.9) | ||
| High | 519 | 2.9 (2.5) | 93.4 (12.0) | ||
|
| 0.59 | 0.29 | |||
| No | 140 | 2.9 (2.6) | 92.1 (11.8) | ||
| Yes | 1467 | 3.0 (2.5) | 93.2 (11.9) | ||
|
| <0.001 | 0.85 | |||
| No | 1515 | 2.9 (2.5) | 93.1 (12.0) | ||
| Yes | 92 | 5.1 (2.8) | 92.8 (9.5) | ||
|
| 0.03 | 0.08 | |||
| ≤1 per month | 1454 | 3.0 (2.5) | 92.9 (11.9) | ||
| >1 per month | 153 | 3.4 (2.9) | 94.7 (11.3) | ||
|
| 0.02 | 0.91 | |||
| Moderate/high | 1003 | 3.1 (2.6) | 93.0 (11.7) | ||
| Low | 604 | 2.8 (2.4) | 93.1 (12.1) | ||
|
| 0.13 | 0.27 | |||
| <1 per day | 767 | 3.1 (2.6) | 93.4 (11.8) | ||
| ≥1 per day | 840 | 2.9 (2.4) | 92.8 (11.9) | ||
|
| 0.33 | 0.002 | |||
| No | 1131 | 3.0 (2.5) | 92.5 (12.0) | ||
| Yes | 476 | 3.1 (2.5) | 94.5 (11.4) | ||
|
| <0.001 | <0.001 | |||
| No | 1190 | 2.4 (1.9) | 88.7 (7.7) | ||
| Yes | 417 | 4.8 (3.2) | 105.6 (12.6) | ||
|
| <0.001 | <0.001 | |||
| Normoglycaemia | 1159 | 2.7 (2.4) | 91.8 (11.1) | ||
| Prediabetes | 272 | 3.5 (2.7) | 95.5 (11.9) | ||
| Type 2 diabetes | 176 | 4.0 (2.7) | 97.6 (14.6) | ||
| Crude model | Adjusted model
| |
|---|---|---|
| β (95% CI) | β (95% CI) | |
|
| ||
|
| ||
| Normoglycemia | Reference | Reference |
| Prediabetes |
|
|
| Type 2 diabetes |
|
|
|
| ||
|
| ||
| Normoglycemia | Reference | Reference |
| Prediabetes |
|
|
| Type 2 diabetes |
|
|
| Crude model | Adjusted model
| |
|---|---|---|
| β (95% CI) | β (95% CI) | |
|
| ||
|
| ||
| Normoglycemia |
|
|
| Prediabetes | -0.06 (-0.31 to 0.18) | -0.06 (-0.30 to 0.16) |
| Type 2 diabetes | -0.16 (-0.51 to 017) | -0.18 (-0.51 to 0.13) |
|
| ||
|
| ||
| Normoglycemia |
|
|
| Prediabetes |
|
|
| Type 2 diabetes |
|
|
- —Wellcome Trust
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetes, Cardiovascular Risks, and Lipoproteins · Blood Pressure and Hypertension Studies · Cardiovascular Health and Risk Factors
Introduction
The number of subjects with cardiovascular diseases (i.e., ischemic heart disease, stroke and others related conditions) is increasing every year, causing 17.3 million deaths annually worldwide, and being considered one of the leading causes of mortality ^ 1 ^. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death in middle-income countries ^ 2 ^, such as Peru.
The increase in cardiovascular events is secondary to the presence of risk factors, which can be classified as modifiable and non-modifiable ^ 3 ^. Latin America, including Peru, is no exception since its population presents a considerable increase in these risk factors ^ 4 ^. For example, a population-based study using data from the National Demographic and Family Health Survey (ENDES in Spanish) reported that the predicted 10-year absolute cardiovascular risk was, on average, 4.5% and 7.8% of the general population had a cardiovascular risk over 10% ^ 5 ^. In addition, the prevalence of hypertension, obesity and smoking, recognized cardiovascular risk factors, has been estimated to be 22.1%, 25.6% and 16.2%, respectively, in 2022 ^ 6 ^.
Simultaneously, glucose metabolism disorders have also increased in recent years globally ^ 7 ^, and Peru is on the same line ^ 8 ^. Thus, the national prevalence of type 2 diabetes was estimated at 7.0% in 2012, and in Lima it reached 8.4% ^ 9 ^, whereas the prevalence of prediabetes fluctuates between 18% and 22% ^ 9, 10 ^. However, in the north of the country, specifically in Tumbes, the prevalence of type 2 diabetes was 11.0% ^ 9 ^, whereas the prevalence of prediabetes may reach levels of 24.0% ^ 11 ^. The disorders of glucose metabolism cause a subsequent insulin resistance with cardiovascular involvement ^ 12, 13 ^. The WHO HEARTS technical package offers a strategic approach to assess and improve cardiovascular health in different contexts and consists of six modules and an implementation guideline, which can be useful for assessing how people's cardiovascular risk varies at the population level but also over time.
Because the prevalence of prediabetes and type 2 diabetes continues to increase in our context, it is necessary to determine the impact of impaired glucose metabolism on cardiovascular risk at the population level, especially in countries with limited economic resources and infrastructure, such as Peru. The most current Peruvian guidelines for the management of type 2 diabetes focuses on its diagnosis and risk factors at the primary care system level ^ 14 ^, but do not promote the management of subjects with elevated cardiovascular risk, especially those with prediabetes.
Therefore, the aim of the present study was to evaluate the change of cardiovascular risk, evaluated by a risk score and mean arterial pressure, according to the levels of glucose metabolism disorder, especially prediabetes and type 2 diabetes.
Methods
Study design
This is a prospective longitudinal cohort study. The baseline was conducted between 2016–2017 and aimed to evaluate the diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) and compare its performance with other risk scores ^ 15 ^. A new evaluation of participants was conducted during 2023, about six years later, by re-contacting all participants who were originally recruited at the baseline.
Study setting and participants
The baseline study was conducted in a representative sample of a peri-urban area of Tumbes, a region located in northern Peru. This setting was chosen because the prevalence of obesity, according to BMI (32% vs. 18%) and type 2 diabetes, according to fasting plasma glucose (10% vs. 7%), was above the national average ^ 11 ^.
The baseline of the study enrolled adult individuals of both sexes, aged between 30 and 69 years, full-time residents (≥6 months) of the study area, eligible for procedures, and who consented participation. We excluded women who reported being pregnant at the moment of enrolment and subjects with some physical disability precluding body measurements (standing height, weight, or waist circumference).
For the present analysis, data from the original study were used provided they contained complete information on the variables of interest (glucose metabolism disorder, variables used for cardiovascular risk estimation and blood pressure measurements). For the prospective analysis, only subjects with complete data at follow-up were considered.
Sampling
Participants were recruited using a single-stage random probability approach, stratified by sex. Data from the most current census at the moment of the cohort’s baseline (2014) were used for the sampling. Only one participant per household was enrolled in the study.
Power calculation was conducted using OpenEpi. OpenEpi is free and open-source software for epidemiologic statistics. It can be run from a web server or downloaded and run without a web connection ^ 16 ^. Assuming that the number of people with type 2 diabetes at baseline was 176 and the number of people with normoglycaemia was 1159, there was close to 100% power to find a difference in cardiovascular risk of 5%. In the case of prediabetes, as the number of cases was greater (n = 272), study power was also close to 100% to find a difference in cardiovascular risk of 5% ^ 10, 15 ^.
Definition of variables
Two were our outcome variables related to cardiovascular risk. The first one was estimated using the risk score WHO HEARTS without laboratory tests, which assesses a person's 10-year cardiovascular risk and is calculated as a percentage using the variables age, sex, smoking status, systolic blood pressure and body mass index (BMI) values ^ 17, 18 ^. The cardiovascular risk was calculated for both baseline and follow-up, using the STATA command whocvdrisk. A free version of the risk calculator is available in Pan-American Health Organization (PAHO) webpage ^ 19 ^. The second outcome was the mean arterial pressure (MAP), calculated using values of systolic (SBP) and diastolic (DBP) blood pressure, estimated at both baseline and follow-up, using the following formula ^ 20 ^:
Glucose metabolism disorder was the exposure of interest, measured at the cohort’s baseline, and defined according to results of the oral glucose tolerance test ^ 21 ^, split into three groups: normoglycaemia (preprandial [fasting] glucose <100 mg/dl and postprandial glucose <140 mg/dl); prediabetes (preprandial glucose between 100 mg/dl and 125 mg/dl, or postprandial glucose between 140 mg/dl and 199 mg/dl); and type 2 diabetes (preprandial glucose ≥126 mg/dl or postprandial glucose ≥200 mg/dl or previous diagnosis of type 2 diabetes made by a physician).
Covariates used for analyses were: age (<40, 40-49, 50-59 or >60 years), sex (male or female), education level (>7, 7-11 and ≥12 years, representing primary, secondary and superior education, respectively), socioeconomic level, based on the household assets and divided into tertiles (low, medium or high), and health insurance (self-report of having or not to health insurance). Additionally, we also included behavioural variables such as smoking (self-reported consumption of at least 1 cigarette per day); alcohol consumption, self-reported and based on the number of times the participant consumed at least six bottles of beer (or equivalent) in the month prior to the survey (≤1 or >1 per month); level of physical activity, based on the International Physical Activity Questionnaire (IPAQ), and categorized according to the number of metabolic equivalents per minute in a week (low vs. moderate/high) ^ 22 ^; fruit and vegetable intake assessed by self-report of consumption of at least 1 fruit or vegetable per day (yes vs. no); presence of obesity, based on body mass index (<30 or ≥30 kg/m ^2^); and arterial hypertension (SBP ≥140 mmHg or SBP ≥90 mmHg or history of previous diagnosis of arterial hypertension) ^ 23 ^. These latter two variables were only used for descriptive purposes.
Procedures
Participants provided written informed consent before commencing data collection. Data were collected using tablets, and trained personnel were responsible for the application of questionnaires (face-to-face) and anthropometric measurements (See Extended Data). The tablets run an application built in Open Data Kit (ODK) for data collection, a free software at the moment of the survey ^ 24 ^.
Once the questionnaires were completed, weight measurements were performed using a bioelectrical impedance device (TBF-300A, TANITA Corporation, Tokyo, Japan), and standing height using a stadiometer and standardized procedures. Blood pressure was assessed in triplicate using an OMRON HEM-780 automatized blood pressure monitor (OMRON Healthcare, Illinois, USA), previously validated for adult population ^ 25 ^.
Participants were explained about procedures for blood sample collection by trained laboratory staff. A venous blood sample (7.5 ml) was drawn from participants after a period of fasting of 8 to 12 hours. Then, a load of 75 g of anhydrous glucose in a volume of 300 ml of water was given. A new blood sample was obtained 2 hours later in order to measure postprandial glucose ^ 21 ^. Questionnaires and clinical measurements were conducted between blood samplings. Blood analyses were performed in a certified laboratory in Lima. A Cobas Modular Platform automated analyser and reagents (number of reagents used 3350, including fasting and postprandial assessments), supplied by Roche Diagnostics (catalogue number: 04404483190). Bio-Rad provided a reference range with respect to quality control for glucose measurements, where <1 was taken for the coefficient of variation.
Statistical analysis
The software used for statistical analysis was STATA 16 for Windows (StataCorp, College Station, TX, US), and a p-value <0.05 was considered statistically significant. To describe the numerical variables, means and standard deviation (SD) were used, whereas categorical variables were reported using frequencies and proportions. To estimate cardiovascular risk (HEARTS), the whocvdrisk command was used, which allows calculation of the 10-year risk in 21 regions of the world ^ 17 ^. Comparison between numerical variables was done using analysis of variance (ANOVA), whereas comparison between categorical variables was conducted using Chi-squared test.
To evaluate the association of interest, crude and adjusted models using mixed linear regression were built, and coefficients (β) and 95% confidence intervals (95% CI) were reported. The multivariable model was adjusted by age, sex, education level, socioeconomic level, health insurance, smoking, alcohol consumption, physical activity level, and fruit and vegetable intake. This procedure was the same for both, the HEARTS score and mean arterial pressure.
Results
Characteristics of the study population
A total of 2114 individuals were invited to participate in the study; of them, 486 (22.9%) declined participation and 16 (0.8%) women were pregnant and were therefore excluded. Of the 1612 (76.3%) participants enrolled in the study, three did not complete the blood procedures and two did not have complete data, therefore, only 1607 subjects were analysed. Of these participants, 50.3% were female, and the mean age was 48 years (SD: 10.5); while 32.2% and 46.6% had primary and secondary education, respectively.
Characteristics of the study population at baseline according to glycaemic status
The prevalence of prediabetes at baseline was 16.9% (95% CI: 15.1% - 18.9%), while that of type 2 diabetes was 11.0% (95% CI: 9.5% - 12.6%). Sex, age, educational level, alcohol use, physical activity level, BMI and the presence of hypertension were factors associated with glycaemic status ( Table 1). Of interest, smoking and fruit or vegetable intake were not associated with the exposure of interest.
Cardiovascular risk according to the characteristics of the study population
The mean cardiovascular risk was 3.0% (SD: 2.5%), whereas the mean arterial pressure was 93.1 (SD: 11.9) mmHg. Cardiovascular risk was higher in males, those of older age, those with lower education, with low socioeconomic status, who reported having smoked, those with higher alcohol consumption, with moderate/high physical activity, with hypertension, and with glycaemic status ( Table 2).
Similarly, mean arterial pressure was, on average, higher among males, those of older age, with low educational level, with obesity, with hypertension, and glycaemia status ( Table 2).
Association between glycaemic status and cardiovascular risk
In the Table 3, our multivariable model using information from study baseline, showed that those with prediabetes and type 2 diabetes had a higher cardiovascular risk and mean blood pressure than participants with normoglycaemia.
After 5.9 (SD: 0.3) years of follow-up, a total of 1197 (74.6%) participants were recontacted. When the change of cardiovascular risk over time was evaluated ( Table 4), an increase in the risk was found among those with normoglycemia, but no change was seen between baseline and follow-up among those with prediabetes and type 2 diabetes. Nevertheless, there was a reduction in the mean arterial pressure, but this was greater in those with normoglycemia than in those with prediabetes and type 2 diabetes.
Discussion
Main findings
Our multivariable model shows that, at the beginning of the cohort, cardiovascular risk was higher among those with type 2 diabetes, then in those with prediabetes, and both groups had a higher cardiovascular risk than those with normoglycaemia. The findings were similar in the case of mean blood pressure, which was higher in people with type 2 diabetes and prediabetes than in those with normoglycaemia. At follow-up, an increase in cardiovascular risk was observed among those with normoglycaemia and no change in those with prediabetes or type 2 diabetes; however, mean arterial pressure had a marked reduction in the three groups, which was more patent among those with normoglycemia at baseline.
Comparison with previous studies
The high cardiovascular risk associated with type 2 diabetes has already been described in previous studies. For example, a systematic review including 57 articles reported that cardiovascular disease affects 32% of people living with diabetes, being one of the major causes of mortality ^ 26 ^. In the case of prediabetes, a systematic review including 53 prospective studies and data from 1.6 million individuals, reported that prediabetes, assessed as a result of fasting glucose, postprandial glucose or glycosylated haemoglobin, was associated with increased cardiovascular risk ^ 27 ^. Thus, the results of our study, at least at the baseline of the cohort, are in relation to previous literature.
Under the same line, a population-based cohort study involving more than 100,000 participants from 20 diverse communities in China concluded that participants with prediabetes and diabetes with 5 or more ideal markers of cardiovascular health had lower excess cardiovascular risk compared with participants with normal glycaemia ^ 13 ^. Thus, these findings highlight the need of having glycaemia and cardiovascular health markers (e.g., blood pressure or cholesterol) controlled in individuals with prediabetes, and more importantly among those with type 2 diabetes diagnosis.
Regarding blood pressure, a cohort study conducted in Japan sought to determine the association of SBP and DBP with the occurrence of a cardiovascular event according to glycaemia status ^ 28 ^. The results indicated that cardiovascular risk increased gradually with increasing SBP and DBP regardless of the degree of glycaemia abnormality. Another study, using data from the US National Health and Nutrition Examination Survey (NHANES) reported a U-shaped relationship between SBP and all-cause mortality regardless of diabetes diagnosis, highlighting the need for appropriate control of blood pressure levels to reduce cardiovascular risk. A study conducted in South Korea analysed data from 5413 participants and reported that progression from a specific glycaemic status to another (i.e., progression from normal glycemia to prediabetes, or from prediabetes to diabetes) was a determinant of increased blood pressure and the development of hypertension ^ 12 ^.
Locally, a prospective cohort study conducted in Peru, analysing data from 3237 participants showed an increase of 2.8 mmHg in SBP and 1.5 mmHg in DBP in subjects with type 2 diabetes after 2.5 years of follow-up ^ 29 ^. Whilst our work evidenced a reduction in mean arterial pressure levels in all three study groups, the reduction was smaller in those with prediabetes and type 2 diabetes. Such drop in blood pressure levels found in our work could be due to several factors, including regression to the mean (i.e., if one sample of a random variable is extreme, the next sampling of the same random variable is likely to be closer to its mean ^ 30 ^); reduction in the number of cases with prediabetes and diabetes, as well as those with risk factors such as obesity, due to the COVID-19 pandemic that occurred between the two evaluations; or appropriate control of blood pressure and glycaemia during the same pandemic period. In any case, the mean arterial pressure level in the study was always higher among those with glucose metabolism disorder than among those without it.
Relevance of findings
The study was conducted in Tumbes, a region of a developing country, where few studies have been carried out to associate glucose metabolism disorders (prediabetes and type 2 diabetes) and cardiovascular risk. Our findings show that those with prediabetes and type 2 diabetes have higher mean arterial pressure than those with normoglycaemia, and this finding is maintained even six years later. This should be considered for appropriate management of these patients.
Despite the fact that prediabetes is highly prevalent, there are usually no procedures for appropriate detection or management in Peru. Even national guidelines focus on the detection, treatment and management of patients with type 2 diabetes ^ 14 ^, but not on those with prediabetes. It is possible that, as patients with type 2 diabetes, those with prediabetes require multidisciplinary management, including cardiovascular, neurologic, ophthalmologic, renal and other evaluations.
In addition, estimating a subject’s cardiovascular risk may require a series of laboratory tests (fasting glucose and total cholesterol), and these are not always available in primary care settings. Our findings show that blood pressure measurement and a laboratory-free cardiovascular risk score could help in the detection and perhaps appropriate management of these patients.
Strengths and limitations
This is a prospective study that allows us to establish temporality between the variables of interest over time. In addition, we used the HEARTS (without laboratory tests), which is a WHO-validated score adaptable to different contexts. However, our study has limitations that deserve discussion. First, as an observational study, only association and not causality can be determined. Second, a potential selection bias may be present since the area chosen for the study does not represent all of Peru, and was selected because high prevalence of obesity and type 2 diabetes. Memory and social desirability bias could be present, especially in the case of variables such as tobacco, used for estimation of the cardiovascular risk, and alcohol consumption. Third, prediabetes is a state that can progress towards type 2 diabetes or revert to normoglycaemia ^ 31 ^; so that in the 6-year follow-up, the change in the condition could affect the final cardiovascular risk. It was not possible to measure glycaemic control at baseline or glycaemic status at follow-up. Finally, a large number of participants were lost to follow-up and could not be contacted because they migrated from the study area due to economic crisis and mortality due to the effect of the COVID-19 pandemic.
Conclusions
This study identified that glucose metabolism disorders are associated with increased cardiovascular risk and mean arterial blood pressure at baseline, and high mean arteria blood pressure after six years. These findings suggest the need for more comprehensive cardiovascular risk monitoring in patients with prediabetes and type 2 diabetes.
Ethics and consent
The present study adhered to the Declaration of Helsinki. The protocol, informed consent and tools used at the study baseline were reviewed and approved by the Institutional Ethics Committees (EIC) of the Universidad Peruana Cayetano Heredia, in Lima, Peru (SIDISI code: 63585, date of approval: February 10, 2015), and the London School of Hygiene and Tropical Medicine (LSHTM), in London, UK (code: 11783, date of approval: October 3, 2016). A written informed consent was read before enrolment to ensure participation.
The protocol, informed consent and tools used in the follow-up were approved by the EIC of the Universidad Peruana Cayetano Heredia (SIDISI code: 209685, date of approval: November 2, 2022). Similar to the baseline, a written informed consent was used before ensure participation.
The present analysis was reviewed and exempted from review by the Research Ethics Committee of the Universidad Científica del Sur.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1GBD 2021 Causes of Death Collaborators: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease study 2021. Lancet. 2024;403(10440):2100–32. 10.1016/S 0140-6736(24)00367-2 38582094 PMC 11126520 · doi ↗ · pubmed ↗
- 2World Health Organization: The top 10 causes of death. Geneva, Switzerland: WHO;2020; [updated 2020; cited 2024 April 12]. Reference Source
- 3Cannon CP : Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007;8(3):11–28. 10.1016/s 1098-3597(07)80025-1 18452839 · doi ↗ · pubmed ↗
- 4NCD Risk Factor Collaboration (NCD-Ris C)—Americas Working Group: Trends in cardiometabolic risk factors in the Americas between 1980 and 2014: a pooled analysis of population-based surveys. Lancet Glob Health. 2020;8(1):e 123–e 33. 10.1016/S 2214-109X(19)30484-X 31839128 PMC 7025323 · doi ↗ · pubmed ↗
- 5Bernabe-Ortiz A Carrillo-Larco RM : Urbanization, altitude and cardiovascular risk. Glob Heart. 2022;17(1): 42. 10.5334/gh.1130 35837362 PMC 9231580 · doi ↗ · pubmed ↗
- 6Instituto Nacional de Estadística e Informática: Perú: enfermedades no transmisibles y transmisibles 2022. Lima, Perú: INEI;2023. Reference Source
- 7NCD Risk Factor Collaboration (NCD-Ris C): Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A 1c. Nat Med. 2023;29(11):2885–901. 10.1038/s 41591-023-02610-2 37946056 PMC 10667106 · doi ↗ · pubmed ↗
- 8Carrillo-Larco RM Bernabé-Ortiz A : [Type 2 diabetes mellitus in peru: a systematic review of prevalence and incidence in the general population]. Rev Peru Med Exp Salud Publica. 2019;36(1):26–36. 10.17843/rpmesp.2019.361.4027 31116335 PMC 7613195 · doi ↗ · pubmed ↗